The University of Pittsburgh’s LifeX project will open its Strip District lab for entrepreneurs in March, a first-of-its-kind facility in Pittsburgh intended to speed new pharmaceuticals and medical devices to market in meeting critical health needs.

Twelve to 15 promising startup businesses will comprise the first class to occupy the planned 20,000-square-foot space, LifeX CEO Dietrich Stephan said Tuesday. The center will offer business mentoring, as well as financial and legal help, to startups addressing some of the toughest problems in health care, including aggressive brain cancer and antibiotic-resistant bacteria.

“Our focus is on very large, obvious, unmet health needs,” said Mr. Stephan, a veteran entrepreneur and chair of the department of human genetics at Pitt’s Graduate School of Public Health.

“We create solutions for people who are suffering and dying. It’s about impact. We need to rock and roll right out of the box.”

Advertise with us

Mr. Stephan outlined the LifeX project at a presentation sponsored by Bio Breakfast, a networking event held at the Pittsburgh Technology Center in South Oakland. A site in the Strip District for the new lab has been identified, but the exact location wasn’t disclosed pending the signing of a building lease.

Among the startups that will move into the new space are Peptilogics Inc., Western Oncolytics and Sharp Edge Labs Inc.

Advisers from Columbus, Ohio-based Huntington Bank and Silicon Valley Bank of Santa Clara, Calif., will offer tenants financing and San Francisco-based Wilson Sonsini Goodrich & Rasati will offer legal counsel, including advice on intellectual property matters, Mr. Stephan said.

Pittsburgh Supercomputing Center will offer entrepreneurs its expertise and a way to do complex calculations and computer modeling.

Mr. Stephan said LifeX would be differentiated from existing small business incubators, accelerators and coworking spaces in the city that have a broader mission. The goal is to carefully screen life sciences businesses for promise and economic impact.

Advertise with us

Companies involved in the project will benefit from a $25 million seed fund, and later, a larger venture capital fund. Fundraising for the seed fund will close in mid-2018 and fundraising for the second fund, with a target amount yet to be determined, is slated to be completed within a year and a half.

The lab’s first class of companies is tilted toward innovative drug development, partly because the path to commercialization is simpler for pharmaceuticals than for medical devices and diagnostics — two other areas of LifeX’s focus.

The idea is to succeed quickly and new drugs can be the way to do that, Mr. Stephan said.

An 18-month study by the Brookings Institution, a Washington D.C.-based think tank, that was released in September identified the need for a place in Pittsburgh for academic researchers to work shoulder to shoulder with venture capitalists, business mentors and others.

“This is really going to galvanize the commercialization side of life sciences,” said Christian Manders, COO of Uptown-based Promethean LifeSciences Inc. and host of the networking event. “This is going to spur commercialization.”

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699